Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Terminated 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

Cyclophosphamide 3sargramostim 2ibrutinib 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Filgrastim 2zanubrutinib 1obinutuzumab 1motesanib diphosphate 1ledipasvir, sofosbuvir drug combination 1ibritumomab tiuxetan 1fludarabine phosphate 1alethine 1XELOX 1Valproic Acid 1Thalidomide 1Radiotherapy 1Psychiatric Rehabilitation 1Pharmacogenomic Testing 1Melphalan 1Leukapheresis 1Ketamine 1Interferon-alpha 1Indium 1Ifosfamide 1Gemcitabine 1Etoposide 1Dexamethasone 1Cytarabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Waldenstrom Macroglobulinemia × ibritumomab tiuxetan × Clear all
NCT00397800 2012-08-28

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Technical University of Munich

Phase 1/2 Unknown
12 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡